Leflunomidă Sandoz (Leflunomide)

Leflunomide works by inhibiting the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. This inhibition limits the proliferation of activated T‑lymphocytes, thereby decreasing the immune‑driven inflammatory response that contributes to joint damage in rheumatoid and psoriatic arthritis.

The dosage of leflunomide is individualized by the prescribing clinician based on the patient’s clinical status, laboratory values, and tolerance. Typically, treatment begins with a loading dose followed by a maintenance dose, but the exact regimen must be determined by a qualified healthcare professional.

Leflunomide is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal malformations and embryotoxicity. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may affect the infant.

To order Leflunomidă Sandoz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The team will then respond with pricing, availability, shipping details (including any required temperature control), and import documentation.

Leflunomide is often compared with methotrexate, another first‑line DMARD for rheumatoid arthritis. While both reduce disease activity, leflunomide has a distinct mechanism—blocking pyrimidine synthesis—whereas methotrexate inhibits folate metabolism. Leflunomide may be preferred in patients who cannot tolerate methotrexate’s hepatic or gastrointestinal side effects, but it carries its own risks such as hepatotoxicity and teratogenicity.

Leflunomidă Sandoz should be stored at temperatures below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use. Do not store in a refrigerator or freezer, as this could affect tablet integrity.

Leflunomidă Sandoz is administered orally, usually as whole tablets swallowed with water. The exact dosing schedule, including any loading dose, is determined by the prescribing physician. Patients should follow the prescriber’s instructions and take the medication consistently at the same time each day to maintain stable drug levels.

The most serious risks associated with leflunomide include severe liver injury, bone‑marrow suppression leading to neutropenia or anemia, pulmonary toxicity such as interstitial lung disease, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, blood counts, and respiratory symptoms.

Leflunomide should not be used by individuals who are pregnant, planning to become pregnant, or are breastfeeding. It is also contraindicated in patients with severe hepatic impairment, active infections, or known hypersensitivity to leflunomide or its metabolites. Clinicians must assess each patient’s medical history before initiating therapy.